drugset / Trial / NCT05953389

Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents

NCT05953389

Phase 2 Active not recruiting 62 enrolled Bioprojet
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Proof of concept, multicenter, randomized, double-blind, placebo-controlled, parallel-group, study to investigate the effect, safety, tolerability and pharmacokinetics of pitolisant in male children and adolescents with Autism Spectrum Disorders.

Timeline

Start
2023-12-20
Primary completion
2025-10
Completion
2025-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitolisant Small molecule 5 mg
Subject Pitolisant Small molecule 10 mg
Subject Pitolisant Small molecule 20 mg
Subject Pitolisant Small molecule 40 mg